53 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
AMGN Amgen Inc. $200.81 $129.98B N/A
Article Searches
Has Amgen (AMGN) Outpaced Other Medical Stocks This Year? http://www.zacks.com/stock/news/590428/has-amgen-amgn-outpaced-other-medical-stocks-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-590428 Oct 29, 2019 - Is (AMGN) Outperforming Other Medical Stocks This Year?
Is a Beat in Store for Amarin (AMRN) This Earnings Season? http://www.zacks.com/stock/news/590830/is-a-beat-in-store-for-amarin-amrn-this-earnings-season?cid=CS-ZC-FT-analyst_blog|earnings_preview-590830 Oct 29, 2019 - Amarin's (AMRN) third-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.
Amgen Inc. (AMGN) CEO Bob Bradway on Q3 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4300172-amgen-inc-amgn-ceo-bob-bradway-q3-2019-results-earnings-call-transcript?source=feed_sector_healthcare Oct 29, 2019 - Amgen Inc. (NASDAQ:AMGN) Q3 2019 Earnings Conference Call October 29, 2019 5:00 PM ET Company Participants Arvind Sood - Vice President, Investor Relations Bob Bradway - Chairman & Chief Executive
Amgen Inc (AMGN) Q3 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2019/10/30/amgen-inc-amgn-q3-2019-earnings-call-transcript.aspx?source=iedfolrf0000001 Oct 30, 2019 - AMGN earnings call for the period ending September 30, 2019.
Bristol-Myers' (BMY) Q3 Earnings & Revenues Beat Estimates http://www.zacks.com/stock/news/596357/bristol-myers-bmy-q3-earnings-revenues-beat-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-596357 Oct 31, 2019 - Bristol-Myers (BMY) beats both earnings and sales estimates in the third quarter, primarily on robust sales of Eliquis and Sprycel.
Allergan (AGN) Meets Q3 Earnings Estimates, Ups '19 Sales View http://www.zacks.com/stock/news/604652/allergan-agn-meets-q3-earnings-estimates-ups-19-sales-view?cid=CS-ZC-FT-analyst_blog|earnings_article-604652 Nov 05, 2019 - Botox, Juveederm fillers, Vraylar drive Allergan's (AGN) third-quarter sales, making up for loss of exclusivity on some brands and lower sales of eye drug, Restasis.
Radius (RDUS) Q3 Earnings Beat Estimates on Tymlos Strength http://www.zacks.com/stock/news/606644/radius-rdus-q3-earnings-beat-estimates-on-tymlos-strength?cid=CS-ZC-FT-analyst_blog|earnings_article-606644 Nov 06, 2019 - Radius (RDUS) reports a narrower-than-expected loss and beats sales estimates in the third quarter of 2019 as Tymlos gains traction.
Amarin (AMRN) Gets FDA Panel Nod for Vascepa Label Expansion http://www.zacks.com/stock/news/621335/amarin-amrn-gets-fda-panel-nod-for-vascepa-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-621335 Nov 15, 2019 - Amarin (AMRN) gets favorable FDA Advisory Committee vote to expand the label of Vascepa capsules to reduce cardiovascular risk in patients with persistent elevated triglycerides.
Bristol-Myers Gets FTC Clearance for Celgene Acquisition http://www.zacks.com/stock/news/625557/bristol-myers-gets-ftc-clearance-for-celgene-acquisition?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-625557 Nov 18, 2019 - Bristol-Myers (BMY) obtains FTC permission for the Celgene acquisition and will divest Otezla to Amgen.
If Biosimilars Are Struggling, Someone Forgot to Tell Coherus BioSciences https://www.fool.com/investing/2019/11/19/if-biosimilars-are-struggling-someone-forgot-to-te.aspx?source=iedfolrf0000001 Nov 19, 2019 - The company's Neulasta biosimilar has generated $232 million in revenue in the first nine months of 2019, but its growth rate will slow soon.

Pages: 123456

Page 1>